Testing Efficacy Or Toxicity Of A Compound Or Composition (e.g., Drug, Vaccine, Etc.) Patents (Class 424/9.2)
-
Patent number: 11918546Abstract: The invention pertains to the use of therapeutically effective amounts of (a) (i) vitamin C and/or selenium and (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; or (b) (i) vitamin C and/or selenium and (iii) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; or (c) a combination of (i), (ii) and (iii); wherein (a), (b) or (c) optionally further comprises vitamin E, in the manufacture of a product for therapeutically improving synaptic connectivity and/or therapeutically supporting memory and/or cognitive function in a human subject in need thereofType: GrantFiled: August 11, 2021Date of Patent: March 5, 2024Assignee: N.V. NutriciaInventor: Mattheus Cornelis de Wilde
-
Patent number: 11897937Abstract: SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRP1alpha-41BBL fusion protein, host-cells expressing the SIRP1alpha-41BBL fusion protein and methods of use thereof.Type: GrantFiled: August 12, 2021Date of Patent: February 13, 2024Assignee: KAHR Medical Ltd.Inventors: Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
-
Patent number: 11891649Abstract: The aspects of the disclosed embodiments relate to method for determining a likelihood of an inflammatory gastrointestinal tract disease. The method includes diluting a biological sample of a human subject and contacting it with 8-anilinonaphthalene-1-sulfonic acid as modulating agent and further with a reagent, said reagent comprising a peroxidase enzyme and a label selected from a europium chloride and terbium chloride. The sample is incubated and excited, and the time-resolved luminescence signal of the label in the sample is measured. If the luminescence signal is at least 112% higher than for a control sample from a human so subject without of an inflammatory intestine disease, an increased likelihood of an inflammatory intestine disease of the human subject is determined.Type: GrantFiled: April 15, 2021Date of Patent: February 6, 2024Assignee: Aqsens Health OyInventors: Janne Kulpakko, Anita Jansen, Riikka Erkkilä
-
Patent number: 11826477Abstract: A nanomedicinal composition comprising a nanocarrier and an antioxidant. The nanocarrier contains a metal organic framework and a porous silicate and/or aluminosilicate matrix. The antioxidant is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating Blastocystis infection.Type: GrantFiled: June 17, 2022Date of Patent: November 28, 2023Assignee: Imam Abdulrahman Bin Faisal UniversityInventors: B. Rabindran Jermy, Vijaya Ravinayagam, Ayman A. Elbadry
-
Patent number: 11786560Abstract: Provided herein is technology relating to immunoisolation of cells and tissues, including, but not exclusively, to compositions, methods, and kits for encapsulating cells and/or tissues within an immunoisolating device to protect the cells/or tissues from host immune rejection.Type: GrantFiled: January 11, 2021Date of Patent: October 17, 2023Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventor: Ariella Shikanov
-
Patent number: 11773447Abstract: The invention provides compositions, methods, and systems for using cell-free RNA for improved detection of rare cells and/or species that are useful for diagnosing and/or monitoring cancer. The invention also provides for compositions, methods, and systems for early detection of cells that are resistant and/or developing resistance to cancer therapies.Type: GrantFiled: November 13, 2015Date of Patent: October 3, 2023Assignee: NANTHEALTH LABS, INC.Inventor: Kathleen Danenberg
-
Patent number: 11723933Abstract: The present invention provides a strain of Bacteroides thetaiotaomicron and derivatives thereof, and the use of said strain or derivatives in treating inflammatory, autoimmune and allergic disorders. The invention also provides pharmaceutical compositions, nutritional supplements, feedstuffs, food products, dietary supplements, and food additives comprising said strain or derivatives.Type: GrantFiled: January 15, 2019Date of Patent: August 15, 2023Assignee: CJ BIOSCIENCE, INC.Inventors: Angela Margaret Patterson, George Grant, Imke Mulder
-
Patent number: 11707505Abstract: The present invention further relates to using vaccinia virus complement control protein (VCP), factor H and/or a complement control protein (CCP)-containing protein as modulator of the entry and/or replication of pathogen(s), wherein the pathogen is a virus or bacteria. The present invention further relates to a method of prevention and/or treatment of influenza A virus (IAV) infection in a subject of need thereof and to a method of modulation of the entry and/or replication of pathogen(s) in a subject of need thereof.Type: GrantFiled: November 15, 2019Date of Patent: July 25, 2023Assignee: KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTREInventors: Futwan Al-Mohanna, Uday Kishore, Katharine Collison, Valarmathy Murugiah, Soad Saleh, Praveen Mathews Varghese
-
Patent number: 11690834Abstract: Presented herein are methods for treating spinal disc degeneration (SDD) by administering to a subject in need thereof, an amount of a SHH signaling pathway activator effective for treating the subject.Type: GrantFiled: June 23, 2018Date of Patent: July 4, 2023Assignee: New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special SurgeryInventor: Chitra Dahia
-
Patent number: 11638728Abstract: Provided herein are compositions and methods comprising microbiome biomarkers of responsiveness/resistance to immunotherapy (e.g., anti-PD1/PD-L1 therapy), and diagnostic, prognostic and therapeutic uses thereof. In particular, the amount, identity, presence, and/or ratio of microflora in the microbiome of a subject is used to determine the responsiveness/resistance of the subject to immunotherapy, and/or the microbiome of a subject is manipulated to enhance the responsiveness of the subject to various immunotherapies and co-therapies.Type: GrantFiled: June 5, 2018Date of Patent: May 2, 2023Assignee: The University of ChicagoInventors: Thomas F. Gajewski, Jason Luke, Riyue Bao, Vyara Matson, Jessica Fessler
-
Patent number: 11607119Abstract: An ingestible capsule for detecting cancerous and non-cancerous tissues in a colon of patient is disclosed. The capsule has a radiation source integrated into the capsule body for illuminating tissues within a colon of the patient. Tissues of the colon are irradiated with radiation from the radiation source to elicit a fluorescence response, and a photon detector measures photons of the fluorescence response. Intensity and fluorescence lifetime of the fluorescence response is determined based on measured photons. A system employing the capsule is configured to distinguish cancerous and non-cancerous tissues based on the determined fluorescence lifetime of the fluorescence response.Type: GrantFiled: December 17, 2018Date of Patent: March 21, 2023Assignee: QATAR UNIVERSITYInventors: Moez Bouali, Mohamad Sawan, Sumaya Al-Maadeed, Ahmed Bouridane
-
Patent number: 11606956Abstract: The present application relates to compositions comprising 4-chloroindole-3-acetic acid (4Cl-IAA) or an analogue thereof, or a combination of the latter, in the form of a potassium salt, a sodium salt or an amine salt. For example, such compositions can be used used in methods for selectively causing damage or mortality to weed.Type: GrantFiled: April 9, 2019Date of Patent: March 21, 2023Assignee: PREMIER TECH TECHNOLOGIES LTÉEInventors: Pierre Talbot, Alain Bélanger, George Kanellos, Shaun Purcell, Paul Lefebvre, Geneviève Roy, Dominique Lequere
-
Patent number: 11564982Abstract: The disclosure provides methods and compositions that are useful to lessen and/or cure bacterial biofilms and treat diseases or disorders associated with biofilms using one or more novel polypeptide vaccines, antibodies, antibody fragments and compositions. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.Type: GrantFiled: January 3, 2018Date of Patent: January 31, 2023Assignee: Research Institute at Nationwide Children's HospitalInventors: Lauren O. Bakaletz, Steven D. Goodman
-
Patent number: 11529342Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.Type: GrantFiled: November 21, 2018Date of Patent: December 20, 2022Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventor: Guochuan Emil Tsai
-
Patent number: 11433120Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) 20-80 wt. % of at least one diacyl glycerol and/or a tocopherol; b) 20-80 wt. % of at least one phosphatidyl choline (PC); c) 5-20 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) up to 20 wt. % polar solvent e) at least one peptide active agent; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.Type: GrantFiled: May 25, 2012Date of Patent: September 6, 2022Assignee: CAMURUS ABInventors: Fredrik Tiberg, Catalin Nistor, Markus Johnsson
-
Patent number: 11427864Abstract: The present invention relates generally to methods and kits for detecting one or more biomarkers, such as an Epidermal Growth Factor Receptor (EGFR) mutation, e.g., T790M mutation, L858R mutation, one or more exon19 insertions and/or one or more exon19 deletions in the EGFR gene, in a biological sample to aid in diagnosis, prognosis, monitoring, or therapy selection for a disease such as, for example, cancer. The methods and kits are useful in aiding in diagnosis, prognosis, monitoring, or therapy selection for lung cancer, e.g., non-small cell lung cancer (NSCLC).Type: GrantFiled: November 17, 2017Date of Patent: August 30, 2022Assignee: Exosome Diagnostics, Inc.Inventors: Johan Karl Olov Skog, Elena Castellanos-Rizaldos, Vasisht Tadigotla, Dominik Grimm, Xuan Zhang, Wei Yu
-
Patent number: 11385181Abstract: Disclosed is a method of determining efficacy of a cosmetic composition to inhibit an atmospheric pollutant from contacting skin, comprising the steps of: (i) filling a sample holder of known dimensions with known amount of said composition to form a layer of defined thickness therein, where said sample holder is amenable to fluorescence-based assay; (ii) depositing, on said layer, a known amount of a model fine particulate matter which resembles an atmospheric pollutant at least in size and which comprises a material responsive to fluorescence microscopy which is excitable by a wavelength (?ex) and which emits radiation (?em) where (?ex)?(?em); (iii) irradiating said composition and said model fine particulate matter by said ?ex and recording intensity of fluorescence at ?em a plurality of times for a defined period during which said model fine particulate matter interacts with said layer; and, (iv) determining, corrected intensity of fluorescence at ?em by the following equation; corrected Intensity=recordeType: GrantFiled: September 2, 2019Date of Patent: July 12, 2022Assignee: CONOPCO, INC.Inventors: Yi Fang, Sheng Meng, Shangchun Yi
-
Patent number: 11376311Abstract: Methods of treating or preventing microbial infection in a subject in need of treatment by administering a therapeutically effective amount of ergothioneine, or functional analog, or prodrug, or salt thereof. Ergothioneine may be advantageously administered in conjunction with lactoferrin.Type: GrantFiled: November 1, 2018Date of Patent: July 5, 2022Assignees: COLORADO SEMINARY, OWNER AND OPERATOR OF UNIVERSITY OF DENVER, THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATEInventors: John Repine, Amani Alhalwani
-
Patent number: 11366102Abstract: A method of predicting the responsiveness of a patient to a pharmaceutical drug by measuring metabolites in a biological sample from the patient is disclosed. Specific drug metabolites in blood from breast cancer patients are analyzed using NMR spectroscopy whereby responsiveness of the human cancer patients before, during and after treatment with a cancer drug is assessed by measuring the change in clinical outcomes. Data obtained is used to identify particular NMR resonances that are strongly correlated with whether the patient is responsive or resistant to each drug. As such, models for predicting the responsiveness of a patient to each drug based on metabolites from the patient are provided.Type: GrantFiled: October 9, 2019Date of Patent: June 21, 2022Assignee: Olaris, Inc.Inventors: Elizabeth M. O'Day, Chen Dong, Bo Zhang, Srihari Raghavendra Rao
-
Patent number: 11274290Abstract: Methods of enhancing biomass and secondary metabolite accumulation of microalgal species are described herein. A cell culture of the microalgal species were elicited using a combination of techniques for a period of time. Experimental studies compared biomass dry weight production, chlorophyll dry weight content and astaxanthin dry weight content between controls and elicitation treatments. The present invention demonstrated that combined elicitation is an effective method for improving cell biomass growth and astaxanthin production.Type: GrantFiled: November 18, 2019Date of Patent: March 15, 2022Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Joel L. Cuello, Chen-Han Shih
-
Patent number: 11235014Abstract: Provided herein are custom therapeutic compositions combining select Chinese herbs and strains of Cannabis, methods of making the compositions, and methods of using the composition for treatment of headache pain.Type: GrantFiled: April 10, 2020Date of Patent: February 1, 2022Inventor: Artashes Mirzatuny
-
Patent number: 11213581Abstract: The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naïve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.Type: GrantFiled: April 9, 2021Date of Patent: January 4, 2022Assignee: Akston Biosciences CorporationInventors: Todd C. Zion, Thomas M. Lancaster, Thillainayagam Sathiyaseelan, Kexin Huang
-
Patent number: 11207401Abstract: The invention relates to pharmaceutical compositions that contain COVID-19 peptide specific cytotoxic T cells, and to methods for treating or preventing COVID-19 infection.Type: GrantFiled: May 7, 2021Date of Patent: December 28, 2021Assignee: Tevogen Bio Inc.Inventor: Ryan Saadi
-
Patent number: 11179439Abstract: Provided herein are methods and compositions for preventing and treating damage to the heart subsequent to myocardial infarction (MI) resulting from harmful fibrotic remodeling, thereby improving cardiac function and reducing mortality from subsequent heart failure.Type: GrantFiled: June 18, 2019Date of Patent: November 23, 2021Assignees: MandalMed, Inc., The Regents of the University of CaliforniaInventors: Constance M. John, Meenakshi Gaur, Matthew L. Springer, Xiaoyin Wang
-
Patent number: 11179395Abstract: Provided herein are methods for treating melanoma in a subject.Type: GrantFiled: March 16, 2018Date of Patent: November 23, 2021Assignee: GEORGETOWN UNIVERSITYInventors: Sivanesan Dakshanamurthy, Stephen W. Byers, Dean Rosenthal
-
Patent number: 11173218Abstract: Biocompatible polymeric nanoparticles may include: a biocompatible polymer and/or functional metal nanostructures. The biocompatible polymer may be a polyhydroxyalkanoate (PHA). The functional metal nanostructures may include at least one noble metal, at least one magnetic metal oxide, or mixtures thereof. The biocompatible polymeric nanoparticles may have an average size less than or equal to 200 nanometers (nm).Type: GrantFiled: June 27, 2017Date of Patent: November 16, 2021Assignee: BIO-ON S.P.A.Inventor: Mauro Comes Franchini
-
Patent number: 11130798Abstract: Provided herein are composition comprising novel epitopes of ApoB100, as well as sub-sequences, portions and modifications thereof, and uses thereof for treating adverse cardiovascular events, cardiovascular disease, atherosclerosis and certain liver disorders.Type: GrantFiled: May 18, 2016Date of Patent: September 28, 2021Assignee: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGYInventors: Klaus Ley, Alessandro Sette
-
Patent number: 11104723Abstract: Provided herein are methods and compositions for disrupting biofilms in vitro and in vivo. Also disclosed are antibodies comprising a specified heavy chain (HC) immunoglobulin variable domain sequence and/or a specified light chain (LC) immunoglobulin variable domain sequence.Type: GrantFiled: January 28, 2021Date of Patent: August 31, 2021Assignee: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITALInventors: Steven D. Goodman, Lauren O. Bakaletz
-
Patent number: 11077214Abstract: The present application relates to compositions comprising an iodinated contrast agent and indocyanine green co-encapsulated inside a liposomal carrier, various uses thereof as well as methods for their preparation.Type: GrantFiled: May 26, 2014Date of Patent: August 3, 2021Assignee: University Health NetworkInventors: Jinzi Zheng, David A. Jaffray, Christine Allen
-
Patent number: 11037686Abstract: An information processing apparatus, an information processing method, and an information processing program which are capable of suppressing an increase in consumption of system resources used for suppressing a spread of an infection disease are acquired. An information processing apparatus includes an acquisition unit that acquires information regarding an infection disease of a first animal infected with the infection disease, a specification unit that specifies a second animal positioned within a behavior area of the first animal, a determination unit that determines whether or not the infection disease of the first animal is likely to infect the second animal, and a notification unit that notifies an owner of the second animal of an alarm regarding the infection disease in a case where it is determined that the infection disease of the first animal is likely to infect the second animal.Type: GrantFiled: January 8, 2020Date of Patent: June 15, 2021Assignee: FUJIFILM CORPORATIONInventors: Shigetoshi Ishikawa, Yasuhisa Kaneko, Haruyasu Nakatsugawa
-
Patent number: 11009576Abstract: Described here are systems and methods for volumetric excitation in magnetic resonance imaging (“MRI”) using frequency modulated radio frequency (“RF”) pulses. In general, quadratic phase modulation along the slice encoding direction is implemented for additional spatiotemporal encoding, which better distributes signal content in the slice direction and enables higher acceleration rates that are robust to slice-undersampling.Type: GrantFiled: April 6, 2018Date of Patent: May 18, 2021Assignee: Regents of the University of MinnesotaInventors: Steen Moeller, Mehmet Akcakaya
-
Patent number: 11006892Abstract: The invention relates to a device for assessing the characteristics of the swallowing process in a subject a sensor that is capable of detecting vibrations of the throat during swallowing.Type: GrantFiled: March 19, 2015Date of Patent: May 18, 2021Assignee: Societe des Produits Neslte S.A.Inventors: Michael Jedwab, Adam Burbidge
-
Patent number: 10975127Abstract: The present invention relates to, in part, compositions comprising improved flagellin derived constructs and methods of using for vaccination, including adjuvants comprising flagellin-based agents.Type: GrantFiled: June 24, 2020Date of Patent: April 13, 2021Assignee: Genome Protection, Inc.Inventors: Andrei V. Gudkov, Vadim Mett, Vadim Krivokrysenko
-
Patent number: 10935543Abstract: The present invention relates to a method for determining a level of fat-free body mass (FFM) in a paediatric subject comprising determining a level of phenylacetylglutamine (PAG) in a sample obtained from the subject.Type: GrantFiled: December 30, 2016Date of Patent: March 2, 2021Assignee: Societe des Produits Nestle S.A.Inventors: François-Pierre Martin, Omella Cominetti, Jean-Philippe Godin, Jessica Ezri, Andreas Nydegger
-
Patent number: 10918673Abstract: Provided herein is technology relating to immunoisolation of cells and tissues, including, but not exclusively, to compositions, methods, and kits for encapsulating cells and/or tissues within an immunoisolating device to protect the cells/or tissues from host immune rejection.Type: GrantFiled: August 25, 2016Date of Patent: February 16, 2021Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventor: Ariella Shikanov
-
Patent number: 10912790Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.Type: GrantFiled: April 21, 2016Date of Patent: February 9, 2021Assignee: MiNA THERAPEUTICS LIMITEDInventors: Andreas Wagner, Robert Habib, Hans E. Huber, Pål Sætrom, Endre Bakken Stovner, Markus Hossbach, Monika Krampert, Hans-Peter Vornlocher
-
Patent number: 10914734Abstract: Compositions which comprise a gold nanoparticle, dithiolated diethylenetriamine pentaacetic acid (DTDTPA), and a thioctic acid terminated peptide, wherein the DTDTPA is directly linked to the gold nanoparticle surface via an Au—S bond, and wherein the thioctic acid terminated peptide is directly linked to the gold nanoparticle surface via an Au—S bond.Type: GrantFiled: December 20, 2018Date of Patent: February 9, 2021Assignee: The Curators of the University of MissouriInventors: Raghuraman Kannan, Ajit Zambre, Anandhi Upendran
-
Patent number: 10912456Abstract: A system, method and computer program product for estimating future axial elongation of an individual's eye as a way to predict and track refractive error progression of an individual. The method includes: receiving, via a computer interface, data relating to refractive change in a prior pre-determined time period for the individual from a reference timepoint; receiving data representing an age of the individual and data representing a current axial length value of the eye as measured at the reference timepoint; calculating, by said processor, a future axial elongation of the eye as a function of the age of the individual, the current axial length value of the eye as measured at the reference timepoint, and the refractive change in the prior pre-determined time period; generating, an output indication of said computed axial elongation of the eye, and using said output indication to select a myopia control treatment for said individual.Type: GrantFiled: April 13, 2018Date of Patent: February 9, 2021Assignee: Johnson & Johnson Vision Care, Inc.Inventors: Noel A. Brennan, Xu Cheng
-
Patent number: 10880378Abstract: One embodiment provides a method, including: receiving, at an information handling device, an indication to initiate a contextual session associated with a context; receiving, at the device, at least one context input during a duration of the contextual session; and responsive to receiving the at least one context input, extending the duration of the contextual session, wherein the extended duration does not require receipt of subsequent indications. Other aspects are described and claimed.Type: GrantFiled: November 18, 2016Date of Patent: December 29, 2020Assignee: Lenovo (Singapore) Pte. Ltd.Inventors: Russell Speight VanBlon, Arnold S. Weksler, John Carl Mese, Nathan J. Peterson
-
Patent number: 10801028Abstract: An isolated nucleic acid agent is disclosed comprising a nucleic acid sequence which downregulates expression of a gene product of a Varroa destructor mite. Compositions comprising same and uses thereof are also disclosed.Type: GrantFiled: April 26, 2017Date of Patent: October 13, 2020Assignees: BEEOLOGICS INC., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventors: Ilan Sela, Sharoni Shafir, Eyal Maori, Yael Garbian, Eyal Ben-Chanoch, Gal Yarden, Haim Kalev
-
Patent number: 10759733Abstract: The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.Type: GrantFiled: September 24, 2019Date of Patent: September 1, 2020Assignee: Corsair Pharma, Inc.Inventors: Xiaoming Zhang, Meenakshi S. Venkatraman, Cyrus K. Becker
-
Patent number: 10758602Abstract: The present invention relates to an immunogenic composition comprising: a) one or more antigen of M. hyorhinis and one or more antigens of M. hyosynoviae; and b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to an immunogenic composition that comprises a) one or more mycoplasma antigens of mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae; and b) one or more components of a eukaryotic cell system. Moreover, the present invention also provides an immunogenic composition obtained by a method comprising a) cultivation of a mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae in a serum-reduced, eukaryotic cell system; b) obtaining an antigen of such mycoplasma bacteria; and c) addition of a pharmaceutically acceptable carrier.Type: GrantFiled: December 19, 2017Date of Patent: September 1, 2020Inventors: Dianna M. Murphy Jordan, Brian Thomas Martinson, Christine Margaret Muehlenthaler, Axel Neubauer, Arun V. Iyer
-
Patent number: 10744213Abstract: The present invention discloses fluorescent compounds and a method for their use for selective imaging of blood vessels and blood flow. By applying these fluorescent compounds and the imaging process to a zebrafish model, the present invention further provides methods and procedures for the discovery, selection, and characterization of pro- and anti-angiogenic agents.Type: GrantFiled: February 14, 2017Date of Patent: August 18, 2020Assignee: COLOSSUS BIOPHARMA CONSULTANTS COMPANY, LIMITEDInventor: Jose Mendoza
-
Patent number: 10730915Abstract: The present invention relates to, in part, compositions comprising improved flagellin derived constructs and methods of using for vaccination, including adjuvants comprising flagellin-based agents.Type: GrantFiled: May 16, 2019Date of Patent: August 4, 2020Assignee: Genome Protection, Inc.Inventors: Andrei V. Gudkov, Vadim Mett, Vadim Krivokrysenko
-
Patent number: 10724101Abstract: The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the SCNN1B gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing SCNN1B gene expression or activity.Type: GrantFiled: March 18, 2016Date of Patent: July 28, 2020Assignee: The Chinese University of Hong KongInventors: Jun Yu, Joseph Jao Yiu Sung, Chi Chun Wong
-
Patent number: 10711043Abstract: The disclosure relates to compositions, pharmaceutical compositions, vaccines, and methods of making and using the same. The compositions of the disclosure are useful to stimulate an antigen-specific immune response and, in some embodiments, a protective immune response in an animal after challenge to pathogens. The compositions of the disclosure are also useful for treatment and prevention of disease in a subject such as cancer.Type: GrantFiled: July 9, 2018Date of Patent: July 14, 2020Assignees: University of Maryland, College Park, University of Maryland, BaltimoreInventors: Philip R. DeShong, Lenea Stocker, Daniel C. Stein, Stefanie N. Vogel, Katharina Richard
-
Patent number: 10683257Abstract: The invention provides methods for synthesizing the compound (2R,3S,4E)-N-methyl-5-(4?-pentylphenyl)-2-aminopent-4-ene-1,3-diol, also known as SK1-I, and intermediate compounds used in its synthesis.Type: GrantFiled: May 13, 2019Date of Patent: June 16, 2020Assignee: Enzo Biochem, Inc.Inventors: Zaiguo Li, Natarajan Raju, Praveen Pande
-
Patent number: 10682408Abstract: Embodiments described herein relate to restorative solutions for segmental peripheral nerve (PN) defects using allografted PNs for stimulating PN repair. More specifically, embodiments described herein provide for localized immunosuppression (LIS) surrounding PN allografts as an alternative to systemically suppressing a patient's entire immune system. Methods include localized release of immunosuppressive (ISV) agents are contemplated in one embodiment. Methods also include localized application of immunosuppressive (ISV) regulatory T-cells (Tregs) in other embodiments. Hydrogel carrier materials for delivery of ISV agents and are also described herein.Type: GrantFiled: July 13, 2018Date of Patent: June 16, 2020Assignee: UNIVERSITY OF WYOMINGInventor: Jared Bushman
-
Patent number: 10610147Abstract: Systems and methods of the present invention provide for an olfactometer for delivering one or more odors and one or more computing devices configured to: receive user input for an odor memory test and an odor discrimination test; calculate a score for the odor memory test and the odor discrimination test; calculate a first and second confidence interval threshold and a second confidence interval threshold for a first and second predicted odor memory score respectively, based on a relationship between, respectively, the odor memory test score and odor discrimination test score, and previously-entered performance data queried from the database; and responsive to the score for the odor memory test not being greater than the first confidence interval threshold and the score for the odor discrimination test not being greater than the second confidence interval threshold, generate a report identifying a user as high risk for a neurodegenerative disease.Type: GrantFiled: September 18, 2015Date of Patent: April 7, 2020Assignee: The General Hospital CorporationInventor: Mark W. Albers
-
Patent number: 10604807Abstract: Methods are provided for assessing a clinical response to a glucocorticoid receptor antagonist (GRA) in a human subject and for diagnosing Cushing's syndrome.Type: GrantFiled: May 18, 2016Date of Patent: March 31, 2020Assignee: Corcept Therapeutics, Inc.Inventors: Joseph K. Belanoff, Hazel Hunt, John Francis Unitt, Andreas G. Moraitis